CA2372511A1 - Secreted and transmembrane polypeptides and nucleic acids encoding the same - Google Patents
Secreted and transmembrane polypeptides and nucleic acids encoding the same Download PDFInfo
- Publication number
- CA2372511A1 CA2372511A1 CA002372511A CA2372511A CA2372511A1 CA 2372511 A1 CA2372511 A1 CA 2372511A1 CA 002372511 A CA002372511 A CA 002372511A CA 2372511 A CA2372511 A CA 2372511A CA 2372511 A1 CA2372511 A1 CA 2372511A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- polypeptide
- cell
- acid sequence
- fgfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Abstract
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Claims (39)
1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID
NO:11), Figure 8 (SEQ ID
NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID
NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID
NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID
NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID
NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ
ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID
NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ
ID NO:137) and Figure 74 (SEQ ID NO:139).
NO:11), Figure 8 (SEQ ID
NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID
NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID
NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID
NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID
NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ
ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID
NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ
ID NO:137) and Figure 74 (SEQ ID NO:139).
2. Isolated nucleic acid having at least 80 % nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in Figure 1 (SEQ ID NO:3), Figure 3 (SEQ ID NO:8), Figure 5 (SEQ ID NO:10), Figure 7 (SEQ ID NO:12), Figure 9 (SEQ ID NO:14), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID NO:21), Figure 15 (SEQ ID NO:23), Figure 17 (SEQ ID
NO:28), Figure 19 (SEQ ID NO:31), Figure 21 (SEQ ID NO:38), Figure 23 (SEQ ID
NO:40), Figure 25 (SEQ ID NO:51), Figure 27 (SEQ ID NO:53), Figure 29 (SEQ ID NO:55), Figure 31 (SEQ ID NO:57), Figure 33 (SEQ ID NO:62), Figure 35 (SEQ ID NO:64), Figure 37 (SEQ ID NO:72), Figure 39 (SEQ ID
NO:77), Figure 41 (SEQ ID NO:79), Figure 43 (SEQ ID NO:83), Figure 45 (SEQ ID
NO:85), Figure 47 (SEQ ID NO:90), Figure 49 (SEQ ID NO:98), Figure 51 (SEQ ID NO:103), Figure 53 (SEQ ID NO:105), Figure 55 (SEQ ID NO:107), Figure 57 (SEQ ID NO:109), Figure 59 (SEQ ID
NO:114), Figure 61 (SEQ
ID NO:120), Figure 63 (SEQ ID NO:125), Figure 65 (SEQ ID NO:127), Figures 67A-B (SEQ ID NO:129), Figure 69 (SEQ ID NO:131), Figure 71 (SEQ ID NO:136) and Figure 73 (SEQ ID
NO:138).
NO:28), Figure 19 (SEQ ID NO:31), Figure 21 (SEQ ID NO:38), Figure 23 (SEQ ID
NO:40), Figure 25 (SEQ ID NO:51), Figure 27 (SEQ ID NO:53), Figure 29 (SEQ ID NO:55), Figure 31 (SEQ ID NO:57), Figure 33 (SEQ ID NO:62), Figure 35 (SEQ ID NO:64), Figure 37 (SEQ ID NO:72), Figure 39 (SEQ ID
NO:77), Figure 41 (SEQ ID NO:79), Figure 43 (SEQ ID NO:83), Figure 45 (SEQ ID
NO:85), Figure 47 (SEQ ID NO:90), Figure 49 (SEQ ID NO:98), Figure 51 (SEQ ID NO:103), Figure 53 (SEQ ID NO:105), Figure 55 (SEQ ID NO:107), Figure 57 (SEQ ID NO:109), Figure 59 (SEQ ID
NO:114), Figure 61 (SEQ
ID NO:120), Figure 63 (SEQ ID NO:125), Figure 65 (SEQ ID NO:127), Figures 67A-B (SEQ ID NO:129), Figure 69 (SEQ ID NO:131), Figure 71 (SEQ ID NO:136) and Figure 73 (SEQ ID
NO:138).
3. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the full-length coding sequence of the nucleotide sequence shown in Figure 1 (SEQ ID NO:3), Figure 3 (SEQ ID NO:8), Figure 5 (SEQ ID
NO:10), Figure 7 (SEQ ID
NO:12), Figure 9 (SEQ ID NO:14), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID
NO:21), Figure 15 (SEQ
ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:31), Figure 21 (SEQ
ID NO:38), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:51), Figure 27 (SEQ ID NO:53), Figure 29 (SEQ ID NO:55), Figure 31 (SEQ ID NO:57), Figure 33 (SEQ ID NO:62), Figure 35 (SEQ ID NO:64), Figure 37 (SEQ ID
NO:72), Figure 39 (SEQ ID NO:77), Figure 41 (SEQ ID NO:79), Figure 43 (SEQ ID
NO:83), Figure 45 (SEQ ID NO:85), Figure 47 (SEQ ID NO:90), Figure 49 (SEQ ID NO:98), Figure 51 (SEQ ID NO:103), Figure 53 (SEQ ID NO:105), Figure 55 (SEQ ID NO:107), Figure 57 (SEQ ID
NO:109), Figure 59 (SEQ
ID NO:114), Figure 61 (SEQ ID NO:120), Figure 63 (SEQ ID NO:125), Figure 65 (SEQ ID NO:127), Figures 67A-B (SEQ ID NO:129), Figure 69 (SEQ ID NO:131), Figure 71 (SEQ ID
NO:136) and Figure 73 (SEQ ID NO:138).
NO:10), Figure 7 (SEQ ID
NO:12), Figure 9 (SEQ ID NO:14), Figure 11 (SEQ ID NO:16), Figure 13 (SEQ ID
NO:21), Figure 15 (SEQ
ID NO:23), Figure 17 (SEQ ID NO:28), Figure 19 (SEQ ID NO:31), Figure 21 (SEQ
ID NO:38), Figure 23 (SEQ ID NO:40), Figure 25 (SEQ ID NO:51), Figure 27 (SEQ ID NO:53), Figure 29 (SEQ ID NO:55), Figure 31 (SEQ ID NO:57), Figure 33 (SEQ ID NO:62), Figure 35 (SEQ ID NO:64), Figure 37 (SEQ ID
NO:72), Figure 39 (SEQ ID NO:77), Figure 41 (SEQ ID NO:79), Figure 43 (SEQ ID
NO:83), Figure 45 (SEQ ID NO:85), Figure 47 (SEQ ID NO:90), Figure 49 (SEQ ID NO:98), Figure 51 (SEQ ID NO:103), Figure 53 (SEQ ID NO:105), Figure 55 (SEQ ID NO:107), Figure 57 (SEQ ID
NO:109), Figure 59 (SEQ
ID NO:114), Figure 61 (SEQ ID NO:120), Figure 63 (SEQ ID NO:125), Figure 65 (SEQ ID NO:127), Figures 67A-B (SEQ ID NO:129), Figure 69 (SEQ ID NO:131), Figure 71 (SEQ ID
NO:136) and Figure 73 (SEQ ID NO:138).
4. Isolated nucleic acid having at least 80% nucleic acid sequence identity to the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 10.
5. A vector comprising the nucleic acid of any one of Claims 1 to 4.
6. The vector of Claim 5 operably linked to control sequences recognized by a host cell transformed with the vector.
7. A host cell comprising the vector of Claim 5.
8. The host cell of Claim 7, wherein said cell is a CHO cell.
9. The host cell of Claim 7, wherein said cell is an E. coli.
10. The host cell of Claim 7, wherein said cell is a yeast cell.
11. A process for producing a PRO polypeptides comprising culturing the host cell of Claim 7 under conditions suitable for expression of said PRO polypeptide and recovering said PRO polypeptide from the cell culture.
12. An isolated polypeptide having at least 80 % amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID
NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID
NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ 1D NO:110), Figure 60 (SEQ ID
NO:115), Figure 62 (SEQ
ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) and Figure 74 (SEQ ID NO:139).
NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID
NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ 1D NO:110), Figure 60 (SEQ ID
NO:115), Figure 62 (SEQ
ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) and Figure 74 (SEQ ID NO:139).
13. An isolated polypeptide scoring at least 80% positives when compared to an amino acid sequence selected from the group consisting of the amino acid sequence shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID
NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID
NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ 1D NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID
NO:115), Figure 62 (SEQ
ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) and Figure 74 (SEQ ID NO:139).
NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID
NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ 1D NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID
NO:115), Figure 62 (SEQ
ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) and Figure 74 (SEQ ID NO:139).
14. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence encoded by the full-length coding sequence of the DNA deposited under any ATCC accession number shown in Table 10.
15. A chimeric molecule comprising a polypeptide according to any one of Claims 12 to 14 fused to a heterologous amino acid sequence.
16. The chimeric molecule of Claim 15, wherein said heterologous amino acid sequence is an epitope tag sequence.
17. The chimeric molecule of Claim 15, wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.
18. An antibody which specifically binds to a polypeptide according to any one of Claims 12 to 14.
19. The antibody of Claim 18, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.
20. Isolated nucleic acid having at least 80% nucleic acid sequence identity to:
(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID
NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID
NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID
NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID
NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID
NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID
NO:130), Figure 70 (SEQ
ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide;
(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID
NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID
NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID
NO:128), Figure 68 (SEQ
ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), with its associated signal peptide; or (c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID
NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID
NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID
NO:128), Figure 68 (SEQ
ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide.
(a) a nucleotide sequence encoding the polypeptide shown in Figure 2 (SEQ ID
NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID
NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID
NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID
NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID
NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID
NO:130), Figure 70 (SEQ
ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide;
(b) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID
NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID
NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID
NO:128), Figure 68 (SEQ
ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), with its associated signal peptide; or (c) a nucleotide sequence encoding an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID
NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID
NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID
NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID
NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID
NO:128), Figure 68 (SEQ
ID NO:130), Figure 70 (SEQ ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide.
21. An isolated polypeptide having at least 80% amino acid sequence identity to:
(a) the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ
ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ
ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID
NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID
NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID
NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ
ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID
NO:132), Figure 72 (SEQ
ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide;
(b) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID
NO:4), Figure 4 (SEQ
ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID
NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID
NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID
NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID
NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID
NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID
NO:130), Figure 70 (SEQ
ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), with its associated signal peptide;
or (c) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID
NO:4), Figure 4 (SEQ
ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID
NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID
NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID
NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID
NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID
NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID
NO:130), Figure 70 (SEQ
ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide.
(a) the polypeptide shown in Figure 2 (SEQ ID NO:4), Figure 4 (SEQ ID NO:9), Figure 6 (SEQ
ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID NO:15), Figure 12 (SEQ
ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID NO:52), Figure 28 (SEQ ID
NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID NO:58), Figure 34 (SEQ ID
NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID NO:91), Figure 50 (SEQ ID
NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID NO:106), Figure 56 (SEQ
ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID NO:130), Figure 70 (SEQ ID
NO:132), Figure 72 (SEQ
ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide;
(b) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID
NO:4), Figure 4 (SEQ
ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID
NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID
NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID
NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID
NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID
NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID
NO:130), Figure 70 (SEQ
ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), with its associated signal peptide;
or (c) an extracellular domain of the polypeptide shown in Figure 2 (SEQ ID
NO:4), Figure 4 (SEQ
ID NO:9), Figure 6 (SEQ ID NO:11), Figure 8 (SEQ ID NO:13), Figure 10 (SEQ ID
NO:15), Figure 12 (SEQ ID NO:17), Figure 14 (SEQ ID NO:22), Figure 16 (SEQ ID NO:24), Figure 18 (SEQ ID NO:29), Figure 20 (SEQ ID NO:32), Figure 22 (SEQ ID NO:39), Figure 24 (SEQ ID NO:41), Figure 26 (SEQ ID
NO:52), Figure 28 (SEQ ID NO:54), Figure 30 (SEQ ID NO:56), Figure 32 (SEQ ID
NO:58), Figure 34 (SEQ ID NO:63), Figure 36 (SEQ ID NO:65), Figure 38 (SEQ ID NO:73), Figure 40 (SEQ ID NO:78), Figure 42 (SEQ ID NO:80), Figure 44 (SEQ ID NO:84), Figure 46 (SEQ ID NO:86), Figure 48 (SEQ ID
NO:91), Figure 50 (SEQ ID NO:99), Figure 52 (SEQ ID NO:104), Figure 54 (SEQ ID
NO:106), Figure 56 (SEQ ID NO:108), Figure 58 (SEQ ID NO:110), Figure 60 (SEQ ID NO:115), Figure 62 (SEQ ID NO:121), Figure 64 (SEQ ID NO:126), Figure 66 (SEQ ID NO:128), Figure 68 (SEQ ID
NO:130), Figure 70 (SEQ
ID NO:132), Figure 72 (SEQ ID NO:137) or Figure 74 (SEQ ID NO:139), lacking its associated signal peptide.
22. A method of detecting a polypeptide designated as A, B, C, D, E, F, G, H, or I in a sample suspected of containing an A, B, C, D, E, F, G, H, or I polypeptide, said method comprising contacting said sample with a polypeptide designated herein as J, K, L, M, N, O, P, Q, R, S or T and determining the formation of a A/J, B/K, C/L, C/M, C/N, C/J, D/O, E/P, F/Q, G/R, H/S or I/T
polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of an A, B, C, D, E, F, G, H, or I polypeptide in said sample and wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F
is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q
is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of an A, B, C, D, E, F, G, H, or I polypeptide in said sample and wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F
is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q
is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
23. The method according to Claim 22, wherein said sample comprises cells suspected of expressing said A, B, C, D, E, F, G, H, or I polypeptide.
24. The method according to Claim 22, wherein said J, K, L, M, N, O, P, Q, R, S or T
polypeptide is labeled with a detectable label.
polypeptide is labeled with a detectable label.
25. The method according to Claim 22, wherein said J, K, L, M, N, O, P, Q, R, S or T
polypeptide is attached to a solid support.
polypeptide is attached to a solid support.
26. A method of detecting a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T in a sample suspected of containing a J, K, L, M, N, O, P, Q, R, S or T
polypeptide, said method comprising contacting said sample with a polypeptide designated herein as A, B, C, D, E, F, G, H, or I and determining the formation of a A/J, B/K, C/L, C/M, C/N, C/J, D/O, E/P, F/Q, G/R, H/S or I/T polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a J, K, L, M, N, O, P, Q, R, S or T polypeptide in said sample and wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I
is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P
is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
polypeptide, said method comprising contacting said sample with a polypeptide designated herein as A, B, C, D, E, F, G, H, or I and determining the formation of a A/J, B/K, C/L, C/M, C/N, C/J, D/O, E/P, F/Q, G/R, H/S or I/T polypeptide conjugate in said sample, wherein the formation of said conjugate is indicative of the presence of a J, K, L, M, N, O, P, Q, R, S or T polypeptide in said sample and wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I
is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P
is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
27. The method according to Claim 26, wherein said sample comprises cells suspected of expressing said J, K, L, M, N, O, P, Q, R, S or T polypeptide.
28. The method according to Claim 26, wherein said A, B, C, D, E, F, G, H, or I polypeptide is labeled with a detectable label.
29. The method according to Claim 26, wherein said A, B, C, D, E, F, G, H, or I polypeptide is attached to a solid support.
30. A method of linking a bioactive molecule to a cell expressing a polypeptide designated as A, B, C, D, E, F, G, H, or I, said method comprising contacting said cell with a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T that is bound to said bioactive molecule and allowing said A, B, C, D, E, F, G, H, or I and said J, K, L, M, N, O, P, Q, R, S or T polypeptides to bind to one another, thereby linking said bioactive molecules to said cell, wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO 187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F
is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q
is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q
is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
31. The method according to Claim 30, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.
32. The method according to Claim 30, wherein said bioactive molecule causes the death of said cell.
33. A method of linking a bioactive molecule to a cell expressing a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T, said method comprising contacting said cell with a polypeptide designated as A, B, C, D, E, F, G, H, or I that is bound to said bioactive molecule and allowing said A, B, C, D, E, F, G, H, or I and said J, K, L, M, N, O, P, Q, R, S or T polypeptides to bind to one another, thereby linking said bioactive molecules to said cell, wherein A is a PRO533 polypeptide, B is a PRO301 polypeptide, C is a PRO187 polypeptide, D is a PRO337 polypeptide, E is a PRO1411 polypeptide, F
is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M
is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
is a PRO10096 polypeptide, G is a PRO246 polypeptide, H is a PRO6307 polypeptide, I is a PRO6003 polypeptide, J is an FGFR-4 polypeptide, K is a PRO301 polypeptide, L is an FGFR-3 polypeptide, M
is an FGFR-1 polypeptide, N is an FGFR-2 polypeptide, O is a PRO6004 polypeptide, P is a PRO4356 polypeptide, Q is a PRO2630 polypeptide, R is a PRO246 polypeptide, S is a PRO265 polypeptide and T is a PRO941 polypeptide.
34. The method according to Claim 33, wherein said bioactive molecule is a toxin, a radiolabel or an antibody.
35. The method according to Claim 33, wherein said bioactive molecule causes the death of said cell.
36. A method of modulating at least one biological activity of a cell expressing a polypeptide designated as A, B, C, D, E, F, G, H, or I, said method comprising contacting said cell with a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T or an anti-A, B, C, D, E, F, G, H, or I polypeptide antibody, whereby said J, K, L, M, N, O, P, Q, R, S or T polypeptide or anti-A, B, C, D, E, F, G, H, or I polypeptide antibody binds to said A, B, C, D, E, F, G, H, or I polypeptide, thereby modulating at least one biological activity of said cell.
37. The method according to Claim 36, wherein said cell is killed.
38. A method of modulating at least one biological activity of a cell expressing a polypeptide designated as J, K, L, M, N, O, P, Q, R, S or T, said method comprising contacting said cell with a polypeptide designated as A, B, C, D, E, F, G, H, or I or an anti-J, K, L, M, N, O, P, Q, R, S or T
polypeptide antibody, whereby said anti-J, K, L, M, N, O, P, Q, R, S or T
polypeptide antibody or A, B, C, D, E, F, G, H, or I polypeptide antibody binds to said J, K, L, M, N, O, P, Q, R, S or T polypeptide, thereby modulating at least one biological activity of said cell.
polypeptide antibody, whereby said anti-J, K, L, M, N, O, P, Q, R, S or T
polypeptide antibody or A, B, C, D, E, F, G, H, or I polypeptide antibody binds to said J, K, L, M, N, O, P, Q, R, S or T polypeptide, thereby modulating at least one biological activity of said cell.
39. The method according to Claim 36, wherein said cell is killed.
Applications Claiming Priority (45)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13969599P | 1999-06-15 | 1999-06-15 | |
US60/139,695 | 1999-06-15 | ||
US14507099P | 1999-07-20 | 1999-07-20 | |
US60/145,070 | 1999-07-20 | ||
US14569899P | 1999-07-26 | 1999-07-26 | |
US60/145,698 | 1999-07-26 | ||
US14939699P | 1999-08-17 | 1999-08-17 | |
US60/149,396 | 1999-08-17 | ||
USPCT/US99/20111 | 1999-09-01 | ||
PCT/US1999/020111 WO2000012708A2 (en) | 1998-09-01 | 1999-09-01 | Further pro polypeptides and sequences thereof |
PCT/US1999/020594 WO2000015666A2 (en) | 1998-09-10 | 1999-09-08 | Compositions and methods for the treatment of tumors |
USPCT/US99/20594 | 1999-09-08 | ||
PCT/US1999/021547 WO2000015797A2 (en) | 1998-09-17 | 1999-09-15 | Compositions and methods for the treatment of immune related diseases |
USPCT/US99/21547 | 1999-09-15 | ||
PCT/US1999/021090 WO2000015796A2 (en) | 1998-09-16 | 1999-09-15 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US99/21090 | 1999-09-15 | ||
PCT/US1999/028313 WO2000032221A2 (en) | 1998-12-01 | 1999-11-30 | Promotion or inhibition of angiogenesis and cardiovascularization |
USPCT/US99/28313 | 1999-11-30 | ||
USPCT/US99/28301 | 1999-12-01 | ||
PCT/US1999/028301 WO2000032776A2 (en) | 1998-12-01 | 1999-12-01 | Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
PCT/US1999/028565 WO2000037638A2 (en) | 1998-12-22 | 1999-12-02 | Methods and compositions for inhibiting neoplastic cell growth |
USPCT/US99/28565 | 1999-12-02 | ||
US16949599P | 1999-12-07 | 1999-12-07 | |
US60/169,495 | 1999-12-07 | ||
PCT/US2000/000219 WO2000053753A2 (en) | 1999-03-08 | 2000-01-05 | Promotion or inhibition of angiogenesis and cardiovascularization |
USPCT/US00/00219 | 2000-01-05 | ||
PCT/US2000/004341 WO2000053756A2 (en) | 1999-03-08 | 2000-02-18 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PCT/US2000/004342 WO2000078961A1 (en) | 1999-06-23 | 2000-02-18 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US00/04341 | 2000-02-18 | ||
USPCT/US00/04342 | 2000-02-18 | ||
PCT/US2000/004414 WO2001004311A1 (en) | 1999-07-07 | 2000-02-22 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US00/04414 | 2000-02-22 | ||
USPCT/US00/05601 | 2000-03-01 | ||
PCT/US2000/005601 WO2000056889A2 (en) | 1999-03-23 | 2000-03-01 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US00/05841 | 2000-03-02 | ||
PCT/US2000/005841 WO2000053758A2 (en) | 1999-03-08 | 2000-03-02 | Compositions and methods for the treatment of immune related diseases |
PCT/US2000/007377 WO2001019991A1 (en) | 1999-09-15 | 2000-03-20 | Compositions and methods for the treatment of immune related diseases |
USPCT/US00/07377 | 2000-03-20 | ||
USPCT/US00/08439 | 2000-03-30 | ||
PCT/US2000/008439 WO2000073454A1 (en) | 1999-06-02 | 2000-03-30 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
USPCT/US00/13358 | 2000-05-15 | ||
PCT/US2000/013358 WO2000075317A2 (en) | 1999-06-09 | 2000-05-15 | Compositions and methods for the treatment of tumor |
USPCT/US00/13705 | 2000-05-17 | ||
PCT/US2000/013705 WO2000073445A2 (en) | 1999-06-02 | 2000-05-17 | Interleukin-1-receptor associated kinase-3 (irak3) |
PCT/US2000/014042 WO2000077037A2 (en) | 1999-06-15 | 2000-05-22 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2372511A1 true CA2372511A1 (en) | 2000-12-21 |
CA2372511C CA2372511C (en) | 2011-11-22 |
Family
ID=36028885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2372511A Expired - Lifetime CA2372511C (en) | 1999-06-15 | 2000-05-22 | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1208195A2 (en) |
JP (6) | JP2003529324A (en) |
AT (2) | ATE449109T1 (en) |
CA (1) | CA2372511C (en) |
WO (1) | WO2000077037A2 (en) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773252A (en) | 1995-06-05 | 1998-06-30 | Human Genome Sciences, Inc. | Fibroblast growth factor 15 |
WO2002008288A2 (en) * | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6506569B1 (en) | 1997-05-30 | 2003-01-14 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR10 |
US6551799B2 (en) | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
WO2002016611A2 (en) * | 2000-08-24 | 2002-02-28 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
US20030190669A1 (en) * | 1998-12-30 | 2003-10-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
ES2308334T3 (en) * | 1999-03-23 | 2008-12-01 | Genentech, Inc. | SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS THAT CODIFY THEM. |
US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
ATE478952T1 (en) | 1999-10-28 | 2010-09-15 | Agensys Inc | 36P6D5: SECRETED TUMOR PROTEIN |
AU2253301A (en) | 1999-12-03 | 2001-06-12 | Zymogenetics Inc. | Human cytokine receptor |
US7226591B2 (en) | 2000-05-22 | 2007-06-05 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
ES2283343T3 (en) * | 1999-12-23 | 2007-11-01 | Kirin Beer Kabushiki Kaisha | METHODS AND MATERIALS RELATED TO POLYPEPTIDES AND SIMILAR POLYNUCLEOTIDES TO THE MOTHER CELL GROWTH FACTOR. |
US20030170823A1 (en) | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
AU6531101A (en) * | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030012788A1 (en) | 2000-07-27 | 2003-01-16 | Jean-Christophe Renauld | Method for influencing kinase pathways with IL-22 |
AU2001283062A1 (en) | 2000-08-02 | 2002-02-13 | The Johns Hopkins University | Endothelial cell expression patterns |
AU2001290524A1 (en) | 2000-08-08 | 2002-02-18 | Zymogenetics Inc. | Soluble zcytor 11 cytokine receptors |
EP1345965A2 (en) * | 2000-12-23 | 2003-09-24 | Kirin Beer Kabushiki Kaisha | Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
JPWO2002064769A1 (en) * | 2001-02-15 | 2004-06-17 | 塩野義製薬株式会社 | New disease markers |
US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
WO2002072811A2 (en) * | 2001-03-13 | 2002-09-19 | Bayer Aktiengesellschaft | Human prenylcysteine lyase-like protein |
CA2439961A1 (en) | 2001-03-27 | 2002-10-03 | Zymogenetics, Inc. | Human cytokine receptor |
JP2005516582A (en) * | 2001-05-25 | 2005-06-09 | アムジェン インコーポレーテッド | Tumor endothelial marker 7α molecule and use thereof |
WO2003013580A1 (en) * | 2001-08-03 | 2003-02-20 | Genset S.A. | Tr xidatin agonists and antagonists treatment of metabolic disorders |
US20030219823A1 (en) * | 2001-09-07 | 2003-11-27 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7205275B2 (en) | 2001-10-11 | 2007-04-17 | Amgen Inc. | Methods of treatment using specific binding agents of human angiopoietin-2 |
US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AU2003207738A1 (en) * | 2002-01-29 | 2003-09-02 | Quark Biotech, Inc. | Islr gene and its association with osteoarthritis and other bone and cartilage disorders, expression products derived therefrom, and uses thereof |
AU2003223344B9 (en) | 2002-03-22 | 2009-07-16 | Zymogenetics, Inc. | Anti-IL-TIF antibodies and methods of using in inflammation |
DE10254601A1 (en) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Gene products differentially expressed in tumors and their use |
EP1606316A2 (en) | 2003-03-24 | 2005-12-21 | ZymoGenetics, Inc. | Anti-il-20 antibodies and binding partners and methods of using in inflammation |
KR101516142B1 (en) | 2003-05-06 | 2015-05-04 | 가부시키가이샤 니콘 | Projection optical system, and exposure apparatus and exposure method |
US7348575B2 (en) | 2003-05-06 | 2008-03-25 | Nikon Corporation | Projection optical system, exposure apparatus, and exposure method |
JP2007520217A (en) * | 2004-01-27 | 2007-07-26 | コンピュゲン ユーエスエイ,インク. | Novel nucleotide and amino acid sequences, and assays and methods of use for breast cancer diagnosis using the same |
DE102004024617A1 (en) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentially expressed in tumors gene products and their use |
AU2005270078A1 (en) | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Compositions and methods for treatment of non-hodgkin's lymphoma |
WO2006026222A2 (en) * | 2004-08-25 | 2006-03-09 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
WO2006047249A1 (en) | 2004-10-22 | 2006-05-04 | Zymogenetics, Inc. | Anti-il-22ra antibodies and binding partners and methods of using in inflammation |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
TWI417301B (en) | 2006-02-21 | 2013-12-01 | Wyeth Corp | Antibodies against human il-22 and uses therefor |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof |
WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
US5824504A (en) * | 1996-09-26 | 1998-10-20 | Elshourbagy; Nabil A. | Human 7-transmembrane receptor and DNA |
US6057435A (en) * | 1997-09-19 | 2000-05-02 | Genentech, Inc. | Tie ligand homologues |
CA2303834A1 (en) * | 1997-09-17 | 1999-03-25 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO1999062925A1 (en) * | 1998-06-02 | 1999-12-09 | Eli Lilly And Company | Angiopoietin related gene sequence scarface 1 |
AU6417799A (en) * | 1998-10-09 | 2000-05-01 | Incyte Pharmaceuticals, Inc. | Matrix-remodeling genes |
-
2000
- 2000-05-22 JP JP2001503894A patent/JP2003529324A/en active Pending
- 2000-05-22 AT AT07025116T patent/ATE449109T1/en not_active IP Right Cessation
- 2000-05-22 AT AT07025118T patent/ATE448246T1/en not_active IP Right Cessation
- 2000-05-22 CA CA2372511A patent/CA2372511C/en not_active Expired - Lifetime
- 2000-05-22 WO PCT/US2000/014042 patent/WO2000077037A2/en not_active Application Discontinuation
- 2000-05-22 EP EP00936172A patent/EP1208195A2/en not_active Withdrawn
-
2005
- 2005-08-15 JP JP2005235120A patent/JP2006068006A/en active Pending
- 2005-08-19 JP JP2005238244A patent/JP2006061156A/en active Pending
- 2005-08-19 JP JP2005238217A patent/JP2006051031A/en active Pending
- 2005-08-19 JP JP2005238274A patent/JP2006051032A/en active Pending
- 2005-08-19 JP JP2005238266A patent/JP2006025795A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2006025795A (en) | 2006-02-02 |
WO2000077037A3 (en) | 2002-02-28 |
JP2006051031A (en) | 2006-02-23 |
ATE449109T1 (en) | 2009-12-15 |
CA2372511C (en) | 2011-11-22 |
JP2006061156A (en) | 2006-03-09 |
JP2003529324A (en) | 2003-10-07 |
EP1208195A2 (en) | 2002-05-29 |
ATE448246T1 (en) | 2009-11-15 |
JP2006068006A (en) | 2006-03-16 |
JP2006051032A (en) | 2006-02-23 |
WO2000077037A2 (en) | 2000-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2372511A1 (en) | Secreted and transmembrane polypeptides and nucleic acids encoding the same | |
CN101704879B (en) | Novel immunoglobulin-binding proteins with improved specificity | |
US5506121A (en) | Fusion peptides with binding activity for streptavidin | |
EP0640135B1 (en) | Immunoglobulin binding proteins derived from l protein and their uses | |
CA2505705A1 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
CA2383424A1 (en) | Novel b7-4 molecules and uses therefor | |
CA2309783A1 (en) | Fibroblast growth factor-19 | |
CN102791726A (en) | Method for purifying immunoglobulin solutions | |
RU2003103099A (en) | INTERFERON-LIKE PROTEIN ZCYTO21 | |
JPWO2006004067A1 (en) | Method for producing protein A-like protein using Brevibacillus bacteria | |
WO2006084388A1 (en) | Monomeric streptavidin muteins | |
EP1114161B1 (en) | Immunoglobulin binding protein | |
JP2022511718A (en) | Anti-Taq DNA polymerase antibody and its uses | |
Harrison et al. | Factors affecting the fermentative production of a lysozyme‐binding antibody fragment in Escherichia coli | |
CA2347649A1 (en) | Mn gene and protein | |
CN104066745A (en) | Use of lysozyme as a tag | |
CN113777295A (en) | High-sensitivity quantum dot probe for detecting tumor marker PD-L1, preparation method and application | |
US20220033484A1 (en) | Antibody against human cardiac troponin I and use thereof | |
US8586315B2 (en) | Fluorescent protein particles | |
CN111925425B (en) | Alpha-fetoprotein specific binding polypeptide and application thereof | |
CN113621079A (en) | Fusion protein of Fab antibody and calf intestinal alkaline phosphatase and preparation method thereof | |
RU2007141407A (en) | COMPOSITIONS AND METHODS WHICH CAN BE USED FOR DIAGNOSIS AND TREATMENT OF TUMORS | |
CN113087807B (en) | Shiga toxin B subunit recombinant protein-based probe for detecting carbohydrate antigen and preparation method thereof | |
CA2669951A1 (en) | Protein particles | |
CN109880840A (en) | A kind of recombinant protein Escherichia coli vivo biodistribution element tagging system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20200522 |